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Introduction
Isocitrate dehydrogenase (IDH) is a member of the 
β-decarboxylating dehydrogenase family of enzymes and cata-
lyzes the oxidative decarboxylation of 2R, 3S-isocitrate to yield 
2-oxoglutarate (α-KG).1 There are three isoforms of IDH namely 
IDH1, IDH2 and IDH3. Somatic mutation of IDH1 at the locus 
of R132 (IDH1R132H) occurs in > 70% of WHO grade II–III 
gliomas and secondary glioblastomas.2 Acute myeloid leukemia 
(AML) is the only non-central nervous system (CNS) tumor 
in which a substantial percentage of the mutations are present 
as well.3 In other cancer types mutation of IDH1 is infrequent. 
A mutation-specific antibody was raised against the mutated 
enzyme (anti-mIDH1R132H) and immunostaining is becom-
ing an alternative screening tool for the presence of the muta-
tion (Dianova GmbH)4 to be applied prior to DNA sequencing. 
In immunostained glioma sections we discovered cells with 
microglial features which appeared to be positive for the mutated 
IDH1R132H. Following up on this observation we initiated the pres-
ent investigation aiming at proving the microglial lineage of these 
immunopositive cells. Elucidation of such IDH1R132H mutant cel-
lular components directs the unravelling glioma tumorigenesis. 
Microglial cells are the resident macrophages participating in the 
active innate immune defense in the CNS. Phagocytosis, as a 
mechanism of innate immune defense, is typically inhibited in 
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gliomas.5,6 Because microglial cells largely arise from bone mar-
row they share functional and physical properties with cells of 
myeloid origin and the common origin may well account for the 
shared genetic changes in glioma and AML. More importantly, 
human glioma-infiltrating microglia/macrophages (GIMs) are 
known to substantially contribute to the tumor mass7 (Fig. 1A). 
In the present study, we specifically explored whether microg-
lial cells/macrophages residing in glioma samples share the 
IDH1R132H mutation with glial tumor cells.
Results and Discussion
The mutation-specific antibody enables robust detection of the 
mutation in routine biopsy samples. The specificity of the anti-
body is confirmed by specifically staining the IDH1R132H mutant 
cells only, while not staining cells in normal or non-neoplastic 
brains4 (Fig. 1B–D). The cellular composition of diffusely infil-
trating gliomas is notoriously heterogeneous. In addition to neo-
plastic glial cells which harbor the IDH1 mutation (Fig. 1K) as 
identified by double positive cells of mIDH1R132H and glial fibril-
lary acidic protein (GFAP, the classical marker for astrocytes), 
tumor samples generally contain reactive glial cells, vascular 
cells and phagocytic elements such as macrophages and microg-
lia. We extended our investigations with a cohort of 60 patients 
with gliomas in which IDH1R132H mutation had previously been 
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Figure 1. mutant iDH1r132H detected in glioma-infiltrating microglia/macrophages (Gims). (A) Gims as labeled by CD68 significantly contribute to the 
cellular components of a glioma. (B) mutant iDH1r132H is not detected in a control brain. (C) mutant iDH1r132H is not detected in glial cells around an AVm. 
(D) mutant iDH1r132H is detected in a glioma. (e) Gims double positive for CD68 and mutant iDH1r132H are shown in overview. (f) Gims double positive for 
iba1 and mutant iDH1r132H are shown in overview. (G) Gims double positive for CX3Cr1 and mutant iDH1r132H are shown in overview. (H) Detail of Gims 
double positive for CD68 and mutant iDH1r132H. (i) Detail of Gims double positive for iba1 and mutant iDH1r132H. (J) Detail of Gims double positive for 
CX3Cr1 and mutant iDH1r132H. (K) Glial tumor cells co-express GfAP and mutant iDH1r132H. (i) mutant iDH1r132H positive cells do not co-express Ki67.
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and microglia/macrophages (Fig. 2). It seems that the expression 
of WT-IDH1 in normal or non-neoplastic brain is restricted to 
cells with high energetic demands, and the expression seems to 
be induced in other cells under pathological situations where cel-
lular energy requirements have increased.
In summary, our findings demonstrate that the cell group of 
microglial cells/macrophages is an important target for IDH1R132H 
mutation in glial tumors. The findings suggest that blood borne 
cells like microglia/macrophages serve as an additional tumor 
component contributing in particular to the tumor infiltrative 
behavior. The data provide novel insights/clues for therapeutic 
strategies against malignant gliomas.
Materials and Methods
Patients and tissue samples. The study was conducted with the 
approval of the institutional ethical review board. A cohort of 
60 patients with gliomas was used for this study. All samples 
were known with IDH1 mutation at locus R132H determined 
by DNA sequence analysis. Control brain samples were from 
autopsy brains without CNS diseases (n = 10) and arteriovenous 
malformations (AVM, n = 6).
Antibodies. Antibodies specifically targeting the IDH1 
R132H mutation (1:250; Dianova GmbH); CD68 (1:150; 
Abbiotec); Iba1 (1:100; Bioss Inc.,); CX3CR1 (1:100; Sigma-
Aldrich); GFAP (1:50; Dako), Ki67 (1:100; Dako) and wild type 
IDH1 (WT IDH1) (1:100; Epitomics) were used for this study. 
Corresponding secondary antibodies conjugated with AP, FITC 
and Cy3 were used.
Immunostaining and confocal laser scanning microscope 
(CLSM). The procedures for immunohistochemistry, double 
immunofluorescent staining and CLSM were performed as pre-
viously published.14-16
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determined by DNA sequence analysis. The mutation was also 
confirmed at the protein level by using the anti-mIDH1R132H anti-
body for each case (Fig. 1D). A cohort of control brains including 
ten non-neoplastic autopsy brains and resection specimens of six 
arteriovenous malformation (AVM) were included in this study, 
and none of these controls appeared to be positive for the anti-
mIDH1R132H (Fig. 1B and C). In order to locate microglial cells/
macrophages, we used CD68, Iba1 and CX3CR1 as markers for 
microglial cells in double immunofluorescence labeling experi-
ments with the anti-mIDH1R132H. Initially, we randomly counted 
200 CD68+ microglial cells in non-overlapping regions in each 
sample and found 26~86% CD68+ microglial cells to be immu-
nopositive for the mutant IDH1R132H (Fig. 1E and H). To further 
confirm the lineage of these cells we used additional microglial 
markers (Iba1 and CX3CR1) in 25 samples, and found 16~68% 
Iba1+ (Fig. 1F and I) and 20~56% CX3CR1+ (Fig. 1G and J) 
microglial cells to be immunopositive for the mutant IDH1R132H. 
Morphological signs of phagocytosis are largely not observable 
in the CD68+, Iba1+ and CX3CR1+ microglia/macrophages. The 
findings demonstrate that part of the IDH1R132H mutant cells are 
either true microglial cells or a fusion of glial tumor cells and 
microgalia/macrophages. It is well-known that macrophages 
are capable of fusing with tumor cells.8 This corroborates the 
hypothesis that microglial cells are actively taking part in glial 
tumorigenesis.9
Tumor progression of gliomas depends on both cellular pro-
liferation and migration which are mutually exclusive phenom-
ena at the level of individual cells.10-12 Microglial cells are highly 
motile and show a distinct migratory behavior. Microglial cells 
fit well into the group of highly migratory cells (invasive tumor 
component) which display little mitotic activity.9,13 Indeed, the 
large majority of mutant IDH1R132H cells did not co-express the 
cell proliferation marker Ki67 (Fig. 1I). These non-glial cells 
harbor genetic aberrations of the tumor cells, reminiscent of 
tumor-macrophage hybrids which have been supposed to be the 
origin of human metastatic cancers by fusogenicity.8 Such fused 
cells would combine the migratory potential of macrophages and 
the proliferative potential of the tumor cells.9 We also examined 
the expression pattern of wild type IDH1 (WT-IDH1) in con-
trol brain samples and WT-IDH1 is largely detected in neurons 
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